Navigation Links
Westaim announces 2009 third quarter results
Date:11/13/2009

l, including but not limited to: (i) failure to complete one or both of the transactions referred to herein; (ii) changes in market conditions or deterioration in underlying investments; (iii) general economic, market, financing, regulatory and industry developments and conditions; and (iv) other risk factors set forth in Westaim's Annual Report or Annual Information Form. Westaim disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

    -------------------------------------------------------------------------
    Three Months Ended
     September 30                 Three Months Ended       Nine Months Ended
    Consolidated Statements             September 30            September 30
     of Operations                  2009        2008        2009        2008
    -------------------------------------------------------------------------

    Revenue                    $   6,672   $   5,466   $  17,644   $  15,428
    Loss from continuing
     operations                      (18)     (1,851)     (3,382)       (511)
    Net loss                        (175)     (3,122)     (4,144)    (12,981)
    Net loss per common share
     - basic and diluted
      Continuing operations        (0.00)      (0.02)      (0.04)      (0.01)
      Net loss                     (0.00)      (0.03)      (0.04)      (0.14)
    Weighted average number
     of common shares
     outstanding (thousands)      94,221      94,215      94,219      94,205


    -------------------------------------------------------------------------
    Three Months Ended            Three Months Ended       Nine Months Ended
     September 30                       September 30            September 30
    Segmented Information           2009        2008        2009        2008
    -----
'/>"/>
SOURCE Westaim Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Westaim announces 2009 second quarter results
2. Westaim announces 2009 first quarter results
3. Westaim enters into Management Services Agreement
4. Westaim announces 2008 year-end results
5. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
6. Westaim announces 2008 third quarter results
7. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Third Quarter Results
8. Westaim terminates reorganization agreement and cancels shareholders meeting
9. Westaim to deregister its common stock in the United States
10. Westaim announces sale of iFire Technology Ltd. assets
11. Westaim announces 2008 second quarter results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... J. Jill Suitor, PhD, of Purdue University as ... to Gerontology Award. , This distinguished honor is ... have helped bring about a new synthesis and ... designs addressing a significant problem in the literature. ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Sean P. Curran, PhD, of ... of the Nathan Shock New Investigator Award. , This ... knowledge about aging through basic biological research. It was ... founding member of GSA and pioneer in gerontological research ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Carole B. Lewis, PT, DPT, ... recipient of the Excellence in Rehabilitation of Aging Persons ... acknowledge outstanding contributions in the field of rehabilitation. The ... or patient care, or publications that may include scholarly ...
(Date:8/1/2014)... Lifeinsurancenomedicalexam.info has released a new blog post explaining ... high cholesterol levels. , Clients who have a ... medical exam life insurance. These plans offer a convenient ... Since there are no medical examinations involved, clients who ... a few minutes. However, this convenience comes at a ...
(Date:8/1/2014)... August 01, 2014 Chilton Medical ... that aims to empower patients and their families ... health care by providing easy, secure access to ... patients instant, web-based access to their health information ... results, medications, allergies, demographic information, visit history, discharge/aftercare ...
Breaking Medicine News(10 mins):Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Chilton Medical Center Launches Online Patient Portal 2
... new project is an interdisciplinary research project covering ... has been awarded EUR 6 million from the ... The project will gather scientists from seven countries, ... University of Gothenburg, Sweden. , Those working on ...
... In the rat race of life, one thing is certain: ... in Molecular Ecology finds the same is true ... most form distinct neighborhoods where they spend the majority of ... lively neighborhoods each with its own personality. But scientists ...
... by Erich Lindemann Community Mental Health Education Center Initiative ... of Professional Psychology BOSTON, May 26 "The ... the needs of 1.5 million soldiers and marines and ... Estimates are as high as 33% that these ...
... connect using technology powered by 100 percent ... N.Y., May 26 Optimum Lightpath, a ... New York metropolitan area businesses, today introduced ... available exclusively through Optimum Lightpath to New ...
... Novel Oral Therapies Will Garner 29 Percent of the ... from Decision ResourcesWALTHAM, Mass., May 26 Decision Resources, ... for pharmaceutical and healthcare issues, finds that the approval ... as the increasing use of current and emerging injectable ...
... helps explain association between the two illnesses , , TUESDAY, ... gum disease (periodontitis) and heart disease has been discovered ... coronary heart disease (CHD) has been known for years, ... confirmed. The University of Kiel team found that the ...
Cached Medicine News:Health News:Sahlgrenska Academy to lead major European project on obesity 2Health News:Returning War Veterans: Challenges in Continuing Mental Health Care After Military and Civilian Trauma 2Health News:Returning War Veterans: Challenges in Continuing Mental Health Care After Military and Civilian Trauma 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 2Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 4Health News:Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018 2Health News:Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018 3Health News:Gum Disease, Heart Disease Share Genetic Link 2
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, ... novel interventional devices to facilitate removal of blood clots, ... from the financing will support EU commercialization of several ... for the Lazarus ReCover™ and Lazarus Cover™ in ... financing reflects investor confidence in the value of our ...
(Date:7/31/2014)... Catylix, Inc. ( Burbank, California ... California ) announced today the formation of ... fluorination products and related chemistry. Developing ... use of substituents that are chemically stable, resistant ... improve binding and bioavailability. Fluorinated functional groups are ...
(Date:7/31/2014)... -- Zacks.com announces the list of stocks featured in the Analyst ... latest news and events impacting stocks and the financial markets. ... BIIB - Free Report ), Gilead (Nasdaq: GILD - ... Report ), AbbVie (NYSE: ABBV - Free Report ) ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... Phase III,clinical trial evaluating the efficacy and safety ... of postmenopausal osteoporosis were,presented at the American Society ... In the non-inferiority study comparing risedronate 150,mg once ... sodium,tablets)] increases in bone mineral density (BMD) were ...
... Sept. 19 Rockwell Medical,Technologies, Inc. (Nasdaq: ... and,developer of concentrates and specialty pharmaceuticals focused ... that it has commenced,enrollment in its Phase ... a physiological iron-maintenance therapy drug. The ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: